Advertisement
Advertisement
SPRY
ARS Pharmaceuticals, Inc. Common Stock
2.79
USDSponsored
+0.14
+5.28%
Nov 06, 15:59 UTC -5
Closed
After-Market
2.77
-0.02
-0.54%
ARS Pharmaceuticals, Inc. Common Stock (SPRY) Earnings
SPRY Earnings Reports
Positive Surprise Ratio
SPRY beat 11 of 24 last estimates.
46%
Next Report
Date of Next Report
Mar 08, 2027
Estimate for Q4 26 (Revenue/ EPS)
$28.65M
/-$0.30
Implied change from Q3 26 (Revenue/ EPS)
-24.03%
/-16.67%
Implied change from Q4 25 (Revenue/ EPS)
+2.00%
/-28.57%
ARS Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Nov 05, 2026, SPRY reported earnings of -0.36 USD per share (EPS) for Q3 26, missing the estimate of -0.32 USD, resulting in a -11.15% surprise. Revenue reached 37.71 million, compared to an expected 42.83 million, with a -11.96% difference. The market reacted with a +5.28% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.30 USD, with revenue projected to reach 28.65 million USD, implying an decrease of -16.67% EPS, and decrease of -24.03% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cronos Group Inc. Common Share
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.03
Actual
$0.04
Surprise
+17.65%
Aclaris Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.12
Surprise
+28.49%
Protara Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.35
Surprise
+6.17%
Minerva Neurosciences, Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.12
Actual
$1.94
Surprise
+1,629.97%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.25
Surprise
-40.06%
ZOETIS INC.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.52
Actual
$1.75
Surprise
+14.64%
Dyne Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.92
Actual
-$1.06
Surprise
-15.57%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.38
Surprise
+1.04%
Aldeyra Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+37.43%
Lipocine Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.36
Actual
-$0.08
Surprise
+77.91%
FAQ
What were ARS Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, ARS Pharmaceuticals, Inc. Common Stock reported EPS of -$0.36, missing estimates by -11.15%, and revenue of $37.71M, -11.96% below expectations.
How did the market react to ARS Pharmaceuticals, Inc. Common Stock's Q3 2026 earnings?
The stock price moved up 5.28%, changed from $2.65 before the earnings release to $2.79 the day after.
When is ARS Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 08, 2027.
What are the forecasts for ARS Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on --
analysts, ARS Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.30 and revenue of $28.65M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.